Loading
A phase 3 trial testing Darovasertib in uveal melanoma, now recruiting.
Neoadjuvant Darovasertib in Primary Uveal Melanoma is a phase 3 interventional study registered as NCT07015190, led by IDEAYA Biosciences, and recruiting on the registry. Official title: A Randomised, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10). Planned enrolment is 520 participants (estimated). The study started in 2026-01-25 and primary completion is expected in 2030-10. No results have been posted on ClinicalTrials.gov.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Darovasertib, Uveal melanoma.
Shares Darovasertib, Uveal melanoma.